Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lpath Inc Cmn A (LPTN)

Lpath Inc Cmn A (LPTN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Lpath Inc Cmn A 4025 SORRENTO VALLEY BLVD. SAN DIEGO CA 92121

www.lpath.com P: 858-678-0800

Description:

Lpath, Inc., headquartered in San Diego, California, is the category leader in lipid-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. It is a biotechnology company whose lead product candidate, ASONEP is a monoclonal antibody against a validated cancer target, sphingosine-1-phosphate (S1P) that is currently in phase I clinical trials for cancer. A second product candidate, iSONEP (the ocular formulation of the S1P antibody), has demonstrated superior results in various preclinical models of age-related macular degeneration (AMD) and retinopathy and is in a Phase 1 clinical trial in wet-AMD patients. Lpath's third product candidate, Lpathomab, is an antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been long recognized as a valid disease target (cancer, neuropathic pain, fibrosis). The company is based in San Diego, California.

Key Statistics

Overview:

Market Capitalization, $K 7,240
Shares Outstanding, K 2,370
Annual Sales, $ 1,600 K
Annual Net Income, $ -10,010 K
Last Quarter Sales, $ 20 K
Last Quarter Net Income, $ -3,700 K
60-Month Beta 0.20
% of Insider Shareholders 4.50%
% of Institutional Shareholders 3.21%

Growth:

1-Year Return -9.01%
3-Year Return -95.14%
5-Year Return -97.49%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 01/05/17
Earnings Per Share ttm -2.79
EPS Growth vs. Prev Qtr -32.09%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-14 on 06/13/16

LPTN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -150.82%
Return-on-Assets % -131.58%
Profit Margin % -625.63%
Debt/Equity 0.00
Price/Sales 4.52
Price/Cash Flow N/A
Price/Book 2.66
Book Value/Share 1.14
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar